Baird Financial Group Inc. Sells 162 Shares of LeMaitre Vascular, Inc. $LMAT

Baird Financial Group Inc. decreased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,019 shares of the medical instruments supplier’s stock after selling 162 shares during the quarter. Baird Financial Group Inc.’s holdings in LeMaitre Vascular were worth $589,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Principal Financial Group Inc. raised its stake in shares of LeMaitre Vascular by 3.0% during the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock valued at $9,385,000 after acquiring an additional 3,248 shares during the last quarter. Compass Planning Associates Inc raised its stake in shares of LeMaitre Vascular by 91.4% during the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier’s stock valued at $988,000 after acquiring an additional 5,623 shares during the last quarter. US Bancorp DE raised its stake in shares of LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 368 shares during the last quarter. Johnson Investment Counsel Inc. raised its stake in shares of LeMaitre Vascular by 34.8% during the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier’s stock valued at $2,469,000 after acquiring an additional 7,603 shares during the last quarter. Finally, Consolidated Planning Corp bought a new position in shares of LeMaitre Vascular during the first quarter valued at about $947,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock opened at $92.64 on Thursday. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.10 billion, a P/E ratio of 44.97, a P/E/G ratio of 2.46 and a beta of 0.79. The business has a fifty day simple moving average of $89.33 and a two-hundred day simple moving average of $86.19. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular’s payout ratio is currently 38.83%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price target for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald raised their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and an average target price of $97.60.

Insider Buying and Selling

In other news, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the transaction, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. The trade was a 37.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares of the company’s stock, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 120,815 shares of company stock worth $11,280,206 in the last 90 days. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.